Retinitis Pigmentosa (RP)Phase 3SLORP PreserveNCT07710196
A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
A Phase 3 study testing NPI-001 in people with Retinitis Pigmentosa (RP) and Usher Syndrome, run by Nacuity Pharmaceuticals, Inc. at 1 site in United States.
Trial summary
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Retinitis Pigmentosa (RP), Usher Syndrome
- What is being tested?
- NPI-001
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteUnited States
- Study dates
- Oct 2026to Apr 2029
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Able to comprehend and willing to sign an informed consent form (OCF) and adhere to the study protocol.
- Diagnosed with RP associated with Usher syndrome.
- EZ width ≥ 500 microns, which includes the fovea in each eye at Visit 1.
- All edges of the EZ area in both eyes can be visualized at Visit 1 (Screening).
- Have at least 20 detectable points on the MAIA grid in at least one eye at the Screening and Baseline visits (same eye for both visits).
- On stable dose of medications associated with other conditions for at least one month.
- Willing to use contraception during study (for anyone of childbearing potential).
Who cannot join
- Concurrent retinal pathologies that result in vision loss or inability to fixate.
- Intraocular surgery within the last two months or capsulotomy within the last month.
- Current or history of uveitis, Coat's disease, diabetic retinopathy, glaucoma, herpes simplex of the eye, or currently has a cataract that prevents visualization of the posterior pole.
- Likely to require cataract surgery within the next 12 months.
- Unstable fixation during microperimetry in either eye at either Screening or Baseline visits.
- Use of any other investigational new drug, or participation in another clinical trial within 12 weeks before the start of study treatment.
Show all 19Show fewer
- Use of N-acetylcysteine containing products in the previous 30 days prior to the baseline visit or unwilling to refrain from such supplements for the duration of the study.
- Chronic liver or kidney disease, cystic fibrosis, severe asthma, or chronic obstructive pulmonary disease (COPD), history of thrombocytopenia not due to a reversible cause, or other blood dyscrasia.
- Suspected liver dysfunction determined by having alanine aminotransferase (ALT), aspartate aminotransferase (AST), or bilirubin values > 1.5 X the upper limit of normal (ULN) at screening.
- Platelet or hemoglobin values < 100 at screening.
- History of known sensitivity to N-acetylcysteine or similar thiol compounds or any ingredients of NPI-001.
- History of hypersensitivity to any medication or food resulting in systemic symptoms.
- History of cancer (other than non-melanoma skin cancer) diagnosed or requiring treatment within the past 2 years.
- Pregnant women or women planning to become pregnant in the next 25 months or men with partners planning to become pregnant in the next 25 months.
- Lactating women who are breast-feeding.
- Potential participant lives in the same household as a current participant in this study.
- Subjects who are unwilling or unable to refrain from donation of blood from 30 days prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening until 56 days following the last study drug dose administered.
- Inability to provide blood samples, including difficulty with venous access.
- Any reason, in the opinion of the Principal Investigator, the participant should not participate.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Retina Foundation of the Southwest
Dallas, Texas, 75231
Jadan Crow, 214-363-3911 ext. 162, jcrow@retinafoundation.org
About this study
Official title: A 24-Month, Randomized, Double-Masked, Placebo-Controlled Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis PigmentosaAssociated With Usher Syndrome
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are:
Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI-001 to a placebo (a look-alike substance that contains no drug) to see if NPI-001 works to preserve vision.
Participants will:
Take NPI-001 or a placebo twice a day, every day for 24 months and visit the clinic 9 times for checkups and tests.
- Conditions
- Retinitis Pigmentosa (RP), Usher Syndrome
- Being tested
- Placebo, NPI-001
- Medical subject headings
- Retinitis Pigmentosa, Usher Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDrug
Oral placebo tablet
NPI-001Drug
Oral n-acetyl cysteine amide tablet (250mg)
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Oral Placebo Tablet (BID) Receives: Drug: Placebo |
| NPI-001 | Experimental | Oral N-Acetyl Cysteine Amide Tablet (250 mg BID) Receives: Drug: NPI-001 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Ellipsoid Zone Area
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2026
- Study startOct 2026 (estimated)
- Primary completionApr 2029 (estimated)
- Study completionApr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Retinitis Pigmentosa (RP)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Nacuity Pharmaceuticals, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Foundation Fighting Blindness
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07710196
- Sponsor's protocol ID
- C-26-01
- Acronym
- SLORP Preserve
- Status last verified
- Oct 2026
- First submitted
- 13 Jul 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data collected during this trial will not be made available to other researchers.
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 24-Month, Randomized, Double-Masked, Placebo-Controlled Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis PigmentosaAssociated With Usher Syndrome
- ClinicalTrials.gov ID
- NCT07710196
- Acronym / sponsor ID
- SLORP Preserve / C-26-01
- Conditions
- Retinitis Pigmentosa (RP), Usher Syndrome
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Nacuity Pharmaceuticals, Inc.Industry (pharma, biotech, devices)
- Collaborators
- Foundation Fighting Blindness
- Study start
- Oct 2026 (estimated)
- Primary completion
- Apr 2029 (estimated)
- Study completion
- Apr 2029 (estimated)
- First posted
- 17 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are:
Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI-001 to a placebo (a look-alike substance that contains no drug) to see if NPI-001 works to preserve vision.
Participants will:
Take NPI-001 or a placebo twice a day, every day for 24 months and visit the clinic 9 times for checkups and tests.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: PlaceboOral Placebo Tablet (BID) |
| NPI-001 | Experimental | Drug: NPI-001Oral N-Acetyl Cysteine Amide Tablet (250 mg BID) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Able to comprehend and willing to sign an informed consent form (OCF) and adhere to the study protocol.
- Diagnosed with RP associated with Usher syndrome.
- EZ width ≥ 500 microns, which includes the fovea in each eye at Visit 1.
- All edges of the EZ area in both eyes can be visualized at Visit 1 (Screening).
- Have at least 20 detectable points on the MAIA grid in at least one eye at the Screening and Baseline visits (same eye for both visits).
Key exclusion criteria (19 listed)
- Concurrent retinal pathologies that result in vision loss or inability to fixate.
- Intraocular surgery within the last two months or capsulotomy within the last month.
- Current or history of uveitis, Coat's disease, diabetic retinopathy, glaucoma, herpes simplex of the eye, or currently has a cataract that prevents visualization of the posterior pole.
- Likely to require cataract surgery within the next 12 months.
- Unstable fixation during microperimetry in either eye at either Screening or Baseline visits.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboOral placebo tablet | Drug | Placebo |
| NPI-001Oral n-acetyl cysteine amide tablet (250mg) | Drug | NPI-001 |
Primary outcome
Ellipsoid Zone Area
Time frame: 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Individual participant dataSharing planned: No. Individual participant data collected during this trial will not be made available to other researchers.
Related trials for Retinitis Pigmentosa (RP)
Recruiting
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Retinitis Pigmentosa (RP), Rod Cone Dystrophy
RecruitingPhase 2/3
Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)
Retinitis Pigmentosa (RP), Inherited Retinal Diseases
Active, not recruitingPhase 1/2
Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases
Retinitis Pigmentosa (RP), Extensive Macular Atrophy With Pseudodrusen (EMAP)
RecruitingPhase 1/2
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
Primary Photoreceptor Disease, Retinitis Pigmentosa (RP)
RecruitingPhase 1
Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa
Retinitis Pigmentosa (RP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing NPI-001 in people with Retinitis Pigmentosa (RP) and Usher Syndrome, run by Nacuity Pharmaceuticals, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nacuity Pharmaceuticals (+1-817-336-3000, info@nacuity.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ellipsoid Zone Area (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.